亚盛医药Ascentage Pharma（AAPG）2024年环境、社会及管治（ESG）报告「NASDAQ」（英文版）（115页）.pdf

1、Pelcitoclax(APG-1252)APG-2449APG-5918Lisaftoclax(APG-2575)Alrizomadlin(APG-115)Olverembatinib(HQP1351)2024202420242024Environmental,Social Environmental,Social and Governance Reportand Governance ReportEnvironmental,Social Environmental,Social and Governance Reportand Governance Report(Incorporated

2、in the Cayman Islands with limited liability)Stock Code:HKEX:6855 NASDAQ:AAPGAscentage Pharma Group International 1Environmental,Social and Governance Report 2024 Ascentage Pharma Group InternationalPageAbout this Report2Highlights and Performance3Message from Management4About Ascentage Pharma61Corp

3、orate Governance and Solid Foundations71.1Corporate Governance71.2Business Ethics132Global Presence&R&D and Innovation152.1R&D and Innovation152.2Intellectual Property Rights252.3R&D Ethics and Morals263Strict Quality Control and Sustainable Supply283.1Quality and Safety283.2Service Excellence393.3S

4、upply Chain Management414Green Production,Safety Assurance494.1Environmental Management494.2Tackling Climate Change544.3Emission Management644.4Occupational Health and Safety675Empowering Talents to Create Warmth Together735.1Employment735.2Talent Development765.3Care and Welfare835.4Welcoming Commu

5、nity88Appendix I ESG Key Performance Indicators(KPIs)90Appendix II Hong Kong Stock Exchange Environmental,Social and Governance Reporting Code Content Index95Contents2Ascentage Pharma Group International Environmental,Social and Governance Report 2024Environmental,Social and Governance Report 2024Ab

6、out this ReportReport ReviewThis Report is the sixth Environmental,Social and Governance(hereinafter“ESG”)Report published by Ascentage Pharma Group International(hereinafter the“Company”or the“Group”)and its subsidiaries(hereinafter“Ascentage Pharma”or“Ascentage”or“we”or“us”).Reporting GuidelinesTh